Abstract
Product based public-private partnerships (PPPs), of which the International Aids Vaccine Initiative (IAVI) is one, are being developed to try and bridge the gap between scientific and technological potential and the needs of developing countries. First, this paper examines PPP's popularity. Second, we describe key characteristics of IAVI and explain why it differs from more traditional partnerships. Third, IAVI has had some success in bringing new science and technology closer to the world's poor and we look at how it has achieved this success and implications for theoretical and practical approaches to science and technology capacity building.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
